← Back to Search
Intranasal Delivery Of Therapeutic Proteins For Neurological Diseases
F. Malerba, Francesca Paoletti, S. Capsoni, Antonino Cattaneo
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
Introduction: Among the range of therapeutic protein candidates for new generation treatments of neurological diseases, neurotrophic factors and recombinant antibodies hold the greatest potential. However, major difficulties in their safe and effective delivery to the brain severely limit these applications. The BBB restricts the exchange of proteins between the plasma and the CNS. Moreover, therapeutic proteins often need to be selectively targeted to the brain, while minimizing their biodistribution to systemic compartments, to avoid peripheral side effects. The intranasal delivery of proteins has recently emerged as a non-invasive, safe and effective method to target proteins to the CNS, bypassing the BBB and minimizing systemic exposure. Areas covered: We critically summarize the main experimental and mechanistic facts about the simple and non-invasive nasal delivery approach, which provides a promising strategy and a potential solution for the severe unmet medical need of safely and effectively delivering protein therapeutics to the brain. Expert opinion: The intranasal route for the effective delivery of recombinant therapeutic proteins represents an emerging and promising non-invasive strategy. Future studies will achieve a detailed understanding of pharmacokinetic and mechanisms of delivery to optimize formulations and fully exploit the nose-to-brain interface in order to deliver proteins for the treatment of neurological diseases. This expanding research area will most likely produce exciting results in the near future towards new therapeutical approaches for the CNS.
This paper references
Molecular biology of the blood-brain barrier.
W. Pardridge (2005)
Intranasal administration of PEGylated transforming growth factor-alpha improves behavioral deficits in a chronic stroke model.
M. Guerra-Crespo (2010)
Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery
A. Jain (2007)
β-Amyloid Plaques in a Model for Sporadic Alzheimer's Disease Based on Transgenic Anti-Nerve Growth Factor Antibodies
S. Capsoni (2002)
Recombinant protein therapeutics—success rates, market trends and values to 2010
Alex K. Pavlou (2004)
Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte Malerba, Paoletti, Capsoni & Cattaneo Expert Opin. Drug Deliv
M Miyamoto (2001)
Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations.
M. Migliore (2010)
Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches
H. Thoenen (2002)
Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain
Veronica di Fausto (2007)
Nerve growth factor eye drop administrated on the ocular surface of rodents affects the nucleus basalis and septum: Biochemical and structural evidence
A. Lambiase (2007)
Blood-brain barrier delivery.
W. Pardridge (2007)
Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat
H. Baker (2004)
Contribution of extracranial lymphatics and arachnoid villi to the clearance of a CSF tracer in the rat.
M. Boulton (1999)
Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice
P. Das (2003)
The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain.
P. Hadaczek (2006)
Taking Pain Out of NGF: A “Painless” NGF Mutant, Linked to Hereditary Sensory Autonomic Neuropathy Type V, with Full Neurotrophic Activity
S. Capsoni (2011)
Adenovirus-mediated gene transfer in olfactory neurons in vivo.
H. Zhao (1996)
CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.
R. Mandel (2010)
Monoclonals expand into neural disorders
B. Vastag (2006)
Liposome-siRNA-Peptide Complexes Cross the Blood-Brain Barrier and Significantly Decrease PrPC on Neuronal Cells and PrPRES in Infected Cell Cultures
B. Pulford (2010)
Identification of nose-to-brain homing peptide through phage display
Xiao-mei Wan (2009)
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
B. Zlokovic (2008)
Nasal Delivery of High Molecular Weight Drugs
Y. Ozsoy (2009)
Transfer of tritiated water, tyrosine, and propanol from the nasal cavity to cranial arterial blood in rats
N. Einer-Jensen (1999)
Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study
P. Djupesland (2010)
A new generation of noninvasive NGF-based therapies for Alzheimer's Disease
A Cattaneo (2010)
Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
S. Dhuria (2010)
Gene Knockdown in the Olfactory Bulb, Amygdala, and Hypothalamus
I Kim (2009)
Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.
M. Reger (2008)
Delivery of interferon-β to the monkey nervous system following intranasal administration
R. Thorne (2008)
Engineered antibody fragments and the rise of single domains
P. Holliger (2005)
Oxytocin Enhances Amygdala-Dependent, Socially Reinforced Learning and Emotional Empathy in Humans
R. Hurlemann (2010)
Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology?
H. Fehm (2000)
Cerebrovascular Permeability to Peptides: Manipulations of Transport Systems at the Blood-Brain Barrier
B. Zlokovic (2004)
Clearance of amyloid beta-peptide from brain: transport or metabolism?
Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain
E. T. Zhang (2004)
New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules.
D. Teijeiro-Osorio (2009)
Gene Knockdown in the Olfactory Bulb, Amygdala, and Hypothalamus by Intranasal siRNA Administration
The olfactory and respiratory epithelium in rhesus and squirrel monkeys studied with freeze-fracture technique.
B. Engström (1989)
Intranasal insulin improves memory in humans
Christian Benedict (2004)
Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice.
Roberta De Rosa (2005)
Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin‐4/5 in pyramidal cell neuroprotection
N. Royo (2006)
Intranasal drug delivery: how, why and what for?
A. Pires (2009)
Aminated gelatin microspheres as a nasal delivery system for peptide drugs: evaluation of in vitro release and in vivo insulin absorption in rats.
J. Wang (2006)
Filamentous bacteriophage as a novel therapeutic tool for Alzheimer's disease treatment.
B. Solomon (2008)
Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats.
C. Dufès (2003)
Evidence for a ‘Paravascular’ fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space
M. Rennels (1985)
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.
P. Das (2003)
Towards non invasive nerve growth factor therapies for Alzheimer's disease.
Antonino Cattaneo (2008)
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration
R. Thorne (2004)
Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans.
M. Heinrichs (2008)
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse—A microtubule-deficient model of schizophrenia
A. Merenlender-Wagner (2010)
Fenestrated endothelia in vessels of the nasal mucosa
G. Grevers (2004)
Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.
X. Gao (2007)
Delivery of 125I-NGF to the Brain via the Olfactory Route
W. Frey (1997)
Male anorgasmia treated with oxytocin.
W. Ishak (2008)
Anatomy of the Human Nasal Passages
D. M. Clerico (2003)
Nasal administration of cholera toxin B subunit–nerve growth factor improves the space learning and memory abilities in β-amyloid protein25-35-induced amnesic mice
Q. Zhang (2008)
Nanoparticles for direct nose-to-brain delivery of drugs.
Alpesh Mistry (2009)
Mesoangioblasts--vascular progenitors for extravascular mesodermal tissues.
G. Cossu (2003)
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
M. Tuszynski (2005)
Circulating neuroactive peptides and the blood-brain and blood-cerebrospinal fluid barriers.
B. Zlokovic (1990)
Monoclonal antibody successes in the clinic
J. Reichert (2005)
Is nose‐to‐brain transport of drugs in man a reality?
L. Illum (2004)
Filamentous phage as vector-mediated antibody delivery to the brain
D. Frenkel (2002)
Transvascular delivery of small interfering RNA to the central nervous system
P. Kumar (2007)
Evaluation of Direct Transport Pathways of Glycine Receptor Antagonists and an Angiotensin Antagonist from the Nasal Cavity to the Central Nervous System in the Rat Model
S. Charlton (2008)
The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans.
K. Macdonald (2010)
Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia
W. Zhu (2011)
Target site of intranasally sprayed substances and their transport across the nasal mucosa : a new insight into the intranasal route of drug delivery
P Gopinath (1978)
IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis.
J. Engelhardt (1990)
Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration.
X. Gao (2006)
Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype
M. Reger (2006)
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.
J. Price (2001)
Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: A new strategy for the treatment of narcolepsy
LR Hanson (2004)
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
B. Bacskai (2002)
Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
G. Meli (2009)
Trigeminal collaterals in the nasal epithelium and olfactory bulb: A potential route for direct modulation of olfactory information by trigeminal stimuli
Michele L. Schaefer (2002)
Local vascular pathway for progesterone transfer to the brain after nasal administration in gilts.
J. Skipor (2003)
Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.
I. Gozes (2000)
Intranasal insulin improves cognition and modulates beta-amyloid in early AD.
M. Reger (2008)
Monoclonal antibodies as innovative therapeutics.
J. Reichert (2008)
Nasal drug administration: potential for targeted central nervous system delivery.
Candace L. Graff (2005)
Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients
D. Feifel (2010)
Intranasal delivery: physicochemical and therapeutic aspects.
H. Costantino (2007)
Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit.
M. Bradbury (1981)
Strategies to Improve Drug Delivery Across the Blood-Brain Barrier
A. Boer (2007)
Neurogenesis in the adult olfactory neuroepithelium
A. Mackay-Sim (2003)
Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum Disorders
A. Guastella (2010)
Adenovirus-Mediated Gene Transfer in Olfactory Epithelium and Olfactory Bulb: A Long-Term Study
K. Doi (2005)
Neurotrophic factors in the therapy of diabetic neuropathy.
S. Apfel (1999)
Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain
Esther Furrer (2009)
Herpes simplex virus type 1 inoculation enhances hippocampal excitability and seizure susceptibility in mice
H. Wu (2003)
Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice.
S. Capsoni (2009)
New insights into brain BDNF function in normal aging and Alzheimer disease
L. Tapia-Arancibia (2008)
Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy
I. Han (2006)
Purification and acute toxicity of a lectin extracted from tepary bean (Phaseolus acutifolius).
R. Reynoso-Camacho (2003)
Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration
W. Banks (2004)
Intranasal delivery of cells to the brain.
L. Danielyan (2009)
Quantitative analysis of the olfactory pathway for drug delivery to the brain
R. Thorne (1995)
The nerve growth factor 35 years later.
R. Levi-Montalcini (1987)
Original ArticleIntranasal Administration of PEGylated Transforming Growth Factor-α Improves Behavioral Deficits in a Chronic Stroke Model
Magda Guerra-Crespo (2010)
Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway.
X. Chen (1998)
In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type V.
S. Covaceuszach (2010)
Neuronal Activity Drives Localized Blood-Brain-Barrier Transport of Serum Insulin-like Growth Factor-I into the CNS
T. Nishijima (2010)
a new insight into the intranasal route of drug delivery
P Gopinath (2011)
Diagnosis and surveillance of herpes simplex virus infection of the central nervous system
F. Najioullah (2000)
Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes
H. Pollock (1997)
Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.
B. Zlokovic (1996)
Morphology of olfactory epithelium in humans and other vertebrates
E. Morrison (1992)
Intranasal insulin improves cognition and modulates β-amyloid in early AD
M. Reger (2008)
Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats.
M. Miyamoto (2001)
Chapter 17:A New Generation of Noninvasive NGF-Based Therapies for Alzheimer's Disease
Antonino Cattaneo (2010)
Axonal damage markers in cerebrospinal fluid are increased in ALS
J. Brettschneider (2006)
Chitosan as a Novel Nasal Delivery System for Peptide Drugs
L. Illum (2004)
Sniffing neuropeptides: a transnasal approach to the human brain
J. Born (2002)
Development of a non invasive NGF-based therapy for Alzheimer's disease.
S. Covaceuszach (2009)
Controlled particle dispersion: applying vortical flow to optimize nasal drug delivery
M. Giroux (2007)
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease
A. Nagahara (2009)
Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey
B. Balin (1986)
Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats.
A. Lambiase (2005)
Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice.
J. M. Laing (2006)
Intranasal Insulin to Improve Memory Function in Humans
Christian Benedict (2007)
Oxytocin buffers cortisol responses to stress in individuals with impaired emotion regulation abilities
M. Quirin (2011)
Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS
S. R. Alcala-Barraza (2010)
Oxytocin: The great facilitator of life
H. Lee (2009)
Protein therapeutics: a summary and pharmacological classification
B. Leader (2008)
Ciliary Neurotrophic Factor Cell-Based Delivery Prevents Synaptic Impairment and Improves Memory in Mouse Models of Alzheimer's Disease
P. Garcia (2010)
UPTAKE OF ALUMINIUM INTO CENTRAL NERVOUS SYSTEM ALONG NASAL-OLFACTORY PATHWAYS
D. Perl (1987)
Controlled Particle Dispersion™: Applying Vortical Flow to Optimize Nasal Drug Deposition
M. Giroux (2005)
Nerve Growth Factor Gene Therapy in Alzheimer Disease
M. Tuszynski (2007)
ENHANCEMENT OF NASAL ABSORPTION OF CALCITONIN LOADED IN LIPOSOMES
S. Law (2001)
The CNS as a target for peptides and peptide-based drugs
W. Banks (2006)
Nasal delivery of siRNA.
V. Bitko (2008)
Intranasal administration delivers peptoids to the rat central nervous system
T. M. Ross (2008)
UEA I-bearing nanoparticles for brain delivery following intranasal administration.
X. Gao (2007)
BDNF intranasal administration rescues visual memory deficits in a mouse model of Alzheimer disease (AD), the AD11 mouse
N Berardi (2008)
Gene delivery into the central nervous system by nasal instillation in rats.
R. Drăghia (1995)
Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
E. Hollander (2003)
The effect of systemically administered recombinant human nerve growth factor in healthy human subjects
B. Petty (1994)
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
P. Kirsch (2005)
Mesoangioblast-based supplementation of neurotrophic factors for the treatment of neuronal damage
A. Binaschi (2010)
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
I. Gozes (2005)
Role of brain-derived neurotrophic factor in Huntington's disease
C. Zuccato (2007)
Angels and demons: neurotrophic factors and epilepsy.
M. Simonato (2006)
Transport of molecules from nose to brain: Transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium
M. Shipley (1985)
Nasal drug delivery--possibilities, problems and solutions.
L. Illum (2003)
Delivery of Neurotrophic Factors to the Central Nervous System
R. Thorne (2001)
Efficient adenoviral vector-directed expression of a foreign gene to neurons and sustentacular cells in the mouse olfactory neuroepithelium.
A. Holtmaat (1996)
Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice
S. Capsoni (2002)
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
C. Lemere (2010)
Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake.
S. R. K. Vaka (2009)
This paper is referenced by
Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson’s Disease
A. E. Aly (2018)
IGF-I in animal models of muscle wasting , neuromuscular disorders and injury Sarcopenia
Yao-Hua Song (2013)
A therapeutic approach for senile dementias: neuroangiogenesis.
C. Ambrose (2015)
Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats
T. Bender (2015)
Nose-to-brain peptide delivery - The potential of nanotechnology.
Eleni Samaridou (2018)
Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles.
E. Ahmad (2017)
Intranasal “painless” Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1 Mice
S. Capsoni (2012)
Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers.
M. Witting (2015)
TAT modification facilitates nose-to-brain transport of intact mPEG-PDLLA micelles: Evidence from aggregation-caused quenching probes
E. Ahmad (2020)
RECENT DEVELOPMENTS IN TARGETED DRUG DELIVERY SYSTEM FOR CROSSING BLOOD- BRAIN BARRIER: A REVIEW
S. Kumar (2012)
Preliminary studies for the development of intranasal nanoemulsion containing CNS agent: emphasizing the utilization of cut and weigh method
A. Kumar (2017)
Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives
G. Herradón (2014)
Airway delivery of peptides and proteins using nanoparticles.
C. Dombu (2013)
Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice.
Chun Xiao (2013)
The pertussis hypothesis: Bordetella pertussis colonization in the pathogenesis of Alzheimer's disease.
Keith Rubin (2017)
Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier
A. E. Aly (2015)
Noninvasive and targeted drug delivery to the brain using focused ultrasound.
A. Burgess (2013)
Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery.
J. Sarvaiya (2015)
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.
Mihir B. Chauhan (2015)
Neurotrophin delivery using nanotechnology.
A. Angelova (2013)
Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood–brain barrier
X. Wang (2014)
Painless Nerve Growth Factor: A TrkA biased agonist mediating a broad neuroprotection via its actions on microglia cells
Antonino Cattaneo (2019)
A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment.
C. Srisawat (2016)
Intranasal BDNF administration promotes visual function recovery in adult amblyopic rats
Gabriele Sansevero (2019)
The therapeutic potential of IGF-I in skeletal muscle repair
Yao-hua Song (2013)
Insulin mediated novel therapies for the treatment of Alzheimer's disease.
S. K. Dubey (2020)
Pharmacoeconomic Considerations in CNS Drug Development
D. L. Gray (2014)
Delivery of Peptides and Proteins to the Brain Using Nano-Drug Delivery Systems and Other Formulations
D. Stepensky (2016)
4.30 Nanomaterials for Drug Delivery to the Brain
A. Gaudin (2017)
Lamotrigine Lipid Nanoparticles for Effective Treatment of Epilepsy: a Focus on Brain Targeting via Nasal Route
Puja K. Gangurde (2018)
Proneurotrophins Induce Apoptotic Neuronal Death After Controlled Cortical Impact Injury in Adult Mice
Laura Montroull (2020)
Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease
Célia M. C. Faustino (2017)See more